160 related articles for article (PubMed ID: 26297114)
1. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II.
Kinukawa H; Shirakawa T; Yoshimura T
Clin Biochem; 2015 Nov; 48(16-17):1120-5. PubMed ID: 26297114
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
[TBL] [Abstract][Full Text] [Related]
3. gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin.
Naraki T; Kohno N; Saito H; Fujimoto Y; Ohhira M; Morita T; Kohgo Y
Biochim Biophys Acta; 2002 Apr; 1586(3):287-98. PubMed ID: 11997080
[TBL] [Abstract][Full Text] [Related]
4. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
[TBL] [Abstract][Full Text] [Related]
5. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
[TBL] [Abstract][Full Text] [Related]
6. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
7. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
10. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma.
Grosley BM; Hirschauer C; Chambrette B; Bezeaud A; Amiral J
J Lab Clin Med; 1996 Jun; 127(6):553-64. PubMed ID: 8648260
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
13. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
[TBL] [Abstract][Full Text] [Related]
14. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma.
Sugimoto H; Takeda S; Inoue S; Kaneko T; Watanabe K; Nakao A
Liver Int; 2003 Feb; 23(1):38-44. PubMed ID: 12640726
[TBL] [Abstract][Full Text] [Related]
15. Development of up-converting phosphor technology-based lateral flow assay for quantitative detection of serum PIVKA-II: Inception of a near-patient PIVKA-II detection tool.
Huang Y; Zhang S; Zheng Q; Li Y; Yu L; Wu Q; Zheng J; Wu Y; Qiu F; Gao Q; Zhang J
Clin Chim Acta; 2019 Jan; 488():202-208. PubMed ID: 30445030
[TBL] [Abstract][Full Text] [Related]
16. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma.
Uehara S; Gotoh K; Handa H; Tomita H; Senshuu M
J Gastroenterol Hepatol; 2005 Oct; 20(10):1545-52. PubMed ID: 16174072
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
19. Establishment of an enzyme immunoassay using monoclonal antibody (HG1-219) and its application for the diagnosis of hepatocellular carcinoma.
Hada T; Kinoshita Y; Ichimori Y; Imanishi H; Umeyama K; Amuro Y; Toyosaka A; Okamoto E; Higashino K
Jpn J Cancer Res; 1992 Dec; 83(12):1366-72. PubMed ID: 1282911
[TBL] [Abstract][Full Text] [Related]
20. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
Sohn A; Kim H; Yeo I; Kim Y; Son M; Yu SJ; Yoon JH; Kim Y
J Pharm Biomed Anal; 2018 Jul; 156():142-146. PubMed ID: 29702392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
